The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Samsung Medical Center
50 participants
Mar 18, 2024
INTERVENTIONAL
Conditions
Summary
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Eligibility
Inclusion Criteria4
- HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
Exclusion Criteria4
- TNBC breast cancer
- Hormone receptor positive breast cancer
- Non-available FFPE samples
- Treated except T-Dxd
Interventions
1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H\&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06330012